Cortagen
- Category
- Brain & Cognition
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
Cortagen is a tetrapeptide bioregulator marketed for brain aging, cognitive support, and nerve repair. The case rests on animal and mechanistic work, reduced neurological deficit and faster nerve regeneration in preclinical models, while cognitive benefit and gene reactivation in humans are speculative. There is no controlled human safety data, and it is contraindicated in pregnancy. Supply is unregulated research-grade product; not FDA-approved.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Cortagen is a synthetic tetrapeptide developed by Professor Vladimir Khavinson, designed using amino acid analysis of Cortexin, a preparation derived from animal brain tissue. Unlike conventional brain-support compounds that work by altering neurotransmitter levels, Cortagen is theorized to act at the genetic level, entering cell nuclei to regulate gene expression in brain and nerve cells. It is studied primarily for nerve regeneration and protection against brain injury.
How it works in the body
A tetrapeptide with proposed gene-regulatory effects. Studies report chromatin changes in cultured human lymphocytes and altered gene expression in mouse heart; specific regulatory-DNA binding and gene normalization in cortical neurons remain unestablished.
Research overview
Cortagen has been studied primarily in Russian preclinical research since the late 1990s. In rats with severed nerves, intramuscular Cortagen injections increased nerve fiber growth rate by 27% and nerve signal speed by 40%. In cultured lymphocytes from older donors, Cortagen altered chromatin condensation; brain rejuvenation was not tested. Gene expression analysis of over 15,000 genes showed Cortagen altered the activity of 110 known genes in heart tissue. In rats with restricted blood flow to the brain, it accelerated behavioral recovery and protected brain tissue from oxidative damage. No randomized controlled human clinical trials exist, and published research comes mainly from Russian institutions, with Georgian and Italian collaborators, and limited independent replication.
Who researches Cortagen?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching cognitive enhancement
Studied for neuroprotective effects, memory, or cognitive performance.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(8)
Rated by level of concern
No human safety data from controlled clinical trials — risk profile is not well characterized
HighClinicalTrials.gov ('cortagen' — 0 studies); PubMed search 'cortagen' — all indexed records preclinical
Mild injection-site reactions (redness, swelling) reported anecdotally
LowAnecdotal/vendor reporting; no published AE dataset
Contraindicated in pregnancy and breastfeeding due to lack of safety data
HighAbsence of reproductive toxicology in the PubMed record
Patients with severe liver or kidney dysfunction should exercise caution as peptide metabolism/clearance may be altered
LowNo published human PK/ADME data
Potential for hypersensitivity or allergic reactions in susceptible individuals
LowGeneral parenteral peptide class risk; no Cortagen-specific reports
Quality control concerns — as an unregulated research chemical, purity and composition may vary among unregulated products sold online
HighNo FDA approval; PMID 15159690 / 37042594 / 12447482 all state Ala-Glu-Asp-Pro
Long-term effects unknown; no chronic toxicity studies published
HighPubMed search 'cortagen' — no toxicology studies
Epigenetic gene expression changes could theoretically have unpredictable downstream effects, though none have been documented
TheoreticalPMID 15085253; PMID 37042594 (mechanism); no adverse outcome reported
Interaction summary(8)
Rated by direction with this peptide
Immunosuppressants and immunomodulators (e.g. calcineurin inhibitors, biologics)
CautionTheoreticalCortagen activated IL-2 mRNA in mouse splenocytes in vitro, though notably more weakly than Vilon or Epithalon, and in the companion study it produced no thymocyte blast-transformation effect at all. Opposing an intentionally suppressed immune state is therefore mechanistically conceivable but rests on weak in vitro signal and has never been tested in a living organism.
PMID 12447482; PMID 12420072
Cortexin (brain cortex polypeptide extract) and other neurotrophic peptide preparations
NeutralTheoreticalCortagen derives from Cortexin's amino acid profile and the two produced comparable neuroprotective and antioxidant effects in the same rat ischemia model. Overlapping rather than additive activity should be assumed — co-use adds redundancy, not established benefit, so this is duplication rather than synergy.
PMID 21476278
Other Khavinson bioregulators (Epitalon, Thymalin, Vilon, Livagen)
NeutralTheoreticalThese peptides produced the same class effect — ribosomal gene activation and chromatin decondensation — when tested in parallel on lymphocytes from 75–88-year-old subjects, but no combination has ever been studied, so a combined effect is unvalidated rather than demonstrated as safe or synergistic.
PMID 15085253
Cytotoxic chemotherapy and other anti-proliferative or epigenetic therapies (HDAC inhibitors, hypomethylating agents)
CautionTheoreticalA compound whose demonstrated action is derepressing condensed chromatin sits in mechanistic tension with therapies designed to control gene expression or proliferation. No oncology co-administration data of any kind exists; this is reasoning from mechanism, not from an observed interaction.
PMID 37042594; PMID 15085253 (mechanism only)
Antiepileptic drugs / patients with seizure disorders
CautionTheoreticalCortagen is CNS-active in animals — it altered behavioral and recovery endpoints in ischemic rats — but no study has measured cortical excitability, seizure threshold, or any interaction with anticonvulsants. Claims that it 'normalizes cortical neurotransmitter gene expression' are not supported by the indexed literature (the only microarray work was in mouse heart), so this entry is precautionary inference only.
Mechanistic inference from PMID 21476278; no interaction study published
Anticoagulants and antiplatelet agents (warfarin, DOACs, aspirin, clopidogrel)
CautionLowNo pharmacologic interaction is known; the concern is purely procedural — repeated intramuscular or subcutaneous injection carries higher bruising and hematoma risk in anticoagulated patients.
Parenteral route-of-administration risk; no PD/PK interaction data for Cortagen
Antioxidant and neuroprotective agents (alpha-lipoic acid, N-acetylcysteine, citicoline)
NeutralTheoreticalCortagen reduced lipid-peroxidation products in rats, but in that same study serum and cortical antioxidant activity fell rather than rose, so an additive antioxidant effect cannot be assumed in either direction. No combination study exists; treat as unstudied rather than synergistic.
PMID 21476278; PMID 18239817
Cholinesterase inhibitors and nootropics (donepezil, piracetam)
NeutralTheoreticalDifferent mechanistic targets — cholinergic transmission versus chromatin-level gene regulation — with no known metabolic or receptor-level conflict, though no co-administration has been studied.
Mechanistic reasoning; no published interaction data
Known risks(8)
No human safety data from controlled clinical trials — risk profile is not well characterized
Mild injection-site reactions (redness, swelling) reported anecdotally
Contraindicated in pregnancy and breastfeeding due to lack of safety data
Patients with severe liver or kidney dysfunction should exercise caution as peptide metabolism/clearance may be altered
Potential for hypersensitivity or allergic reactions in susceptible individuals
Quality control concerns — as an unregulated research chemical, purity and composition may vary among unregulated products sold online
Long-term effects unknown; no chronic toxicity studies published
Epigenetic gene expression changes could theoretically have unpredictable downstream effects, though none have been documented
Drug interactions(6)
note
No formal drug interaction studies have been conducted for Cortagen. The following are theoretical considerations based on mechanism of action.
Anticoagulants/Antiplatelets
Aspartic acid (Asp) in the sequence may theoretically have mild effects on coagulation pathways. Exercise caution with warfarin, heparin, or aspirin.
Immunosuppressants
Cortagen modulates immune cell gene expression. Theoretical interaction with cyclosporine, tacrolimus, or corticosteroids that also affect immune function.
Other neuropeptides/nootropics
No adverse interactions with Epitalon, Thymalin, Semax, or Selank have been reported, and formal interaction studies are lacking.
Antiepileptic drugs
Cortagen affects neuronal gene expression and could theoretically interact with drugs like carbamazepine or valproic acid that also modulate gene expression.
general_caution
Due to the absence of pharmacokinetic and pharmacodynamic interaction studies, caution is warranted when combining Cortagen with any medication.
Research & benefits
Evidence base
- Total Studies
- 0
- Human Studies
- 0
PRECLINICAL ONLY — No FDA-approved human clinical trials exist for Cortagen. The evidence base is limited to: (1) In vivo animal studies in rats and mice demonstrating nerve regeneration, neuroprotection from ischemia, gene expression modulation, and behavioral recovery. (2) In vitro/ex vivo studies on chromatin remodeling and epigenetic regulation. (3) Limited human observational reports from Russian clinical practice noting "pronounced therapeutic effects" on posttraumatic peripheral nerve recovery and cardiovascular/cerebrovascular parameters, but these lack the rigor of double-blind placebo-controlled trials. The overall evidence level is LOW by Western clinical standards. Published research includes Russian institutions, a Georgian chromatin study, and Italian–Russian collaboration. Independent replication by Western research groups is absent.
Researched for(6)
Rated by confidence in the evidence
Neuroprotection — reduces neurological deficit and supports brain tissue recovery after ischemic injury in animal models
LowSingle rat study found faster ischemic recovery and reduced oxidative stress, not independently replicated.
PMID 21476278 (Eksp Klin Farmakol 2011)
Peripheral nerve regeneration — significantly enhances nerve fiber growth rate (+27%) and conduction velocity (+40%) post-injury
LowRat studies show faster nerve fiber growth and conduction recovery, but no controlled human trials exist.
PMID 11276314 (Bull Exp Biol Med 2000); PMID 12134478 (Dokl Biol Sci 2002)
Epigenetic rejuvenation — induces deheterochromatinization of aged chromatin, potentially reactivating age-silenced genes
LowHuman leukocyte studies show chromatin decondensation with age, but no clinical rejuvenation outcome demonstrated.
PMID 15085253 (Bull Exp Biol Med 2004); PMID 37042594 (Georgian Med News 2023)
Antioxidant support — prevents excessive lipid peroxidation and maintains antioxidant enzyme activity in brain tissues
LowPreclinical studies conflict: one preserved antioxidant activity in ischemic rats, another found it suppressed.
PMID 21476278 (ischemic rat model, antioxidant activity preserved); PMID 18239817 (non-ischemic rats, antioxidant activity suppressed)
Gene expression modulation (110+ genes altered in a mouse heart-tissue study)
SpeculativeOne female-mouse heart study found 110 genes altered; neural and immune effects unverified.
PMID 15159690 (Neuro Endocrinol Lett 2004) — female CBA mouse heart cDNA microarray only, 5-day dosing, single non-replicated study. No source exists for gene-expression effects of Cortagen in neural or immune tissue.
Cognitive support — studied for potential improvements in cognitive performance through neural repair and cellular resilience
SpeculativeInferred from rat ischemia recovery data only; no human cognitive trials have been conducted.
PMID 21476278; ClinicalTrials.gov search 'cortagen' — no registered studies
Benefits(7)
Neuroprotection — reduces neurological deficit and supports brain tissue recovery after ischemic injury in animal models
Peripheral nerve regeneration — significantly enhances nerve fiber growth rate (+27%) and conduction velocity (+40%) post-injury
Epigenetic rejuvenation — induces deheterochromatinization of aged chromatin, potentially reactivating age-silenced genes
Antioxidant support — prevents excessive lipid peroxidation and maintains antioxidant enzyme activity in brain tissues
Gene expression modulation (110+ genes altered in a mouse heart-tissue study)
Anti-inflammatory potential — reported to reduce neuroinflammation and modulate autoimmune reactions in preclinical models
Cognitive support — studied for potential improvements in cognitive performance through neural repair and cellular resilience
Key studies(5)
Turchaninova LN, Kolosova LI, Malinin VV, Moiseeva AB, Nozdrachev AD, Khavinson VK
Bulletin of Experimental Biology and Medicine
2000
Intramuscular cortagen (10 mcg/kg for 10 days) increased sciatic nerve fiber growth rate by 27% and conduction velocity by 40% in rats after nerve transection and suturing.
Anisimov SV, Khavinson VKh, Anisimov VN
Neuro Endocrinology Letters
2004
Microarray analysis of 15,000+ transcripts revealed Cortagen altered expression of 234 clones (110 known genes) in mouse heart, with maximum fold changes of +5.42 (upregulation) and -2.86 (downregulation).
Zarubina IV, Shabanov PD
Eksperimentalnaia i Klinicheskaia Farmakologiia
2011
Cortagen accelerated behavioral recovery in ischemic rats, prevented excessive lipid peroxidation, and maintained antioxidant activity in brain tissues. Authors concluded cortagen can increase efficacy of neuroprotective therapy in chronic brain ischemia.
Lezhava T, Monaselidze J, Jokhadze T, Gaiozishvili M
International Journal of Peptide Research and Therapeutics
2015
Cortagen induced deheterochromatinization of total heterochromatin, activated ribosomal gene synthesis via decondensation of satellite stalks of acrocentric chromosomes, and released repressed genes from facultative heterochromatin — showing chromatin changes in cultured lymphocytes, without demonstrating clinical rejuvenation.
Zarubina IV, Shabanov PD
Bulletin of Experimental Biology and Medicine
2016
Peptide preparations including Cortagen reduced severity of neurological deficit, restored individual behavior structure, and demonstrated antioxidant action during chronic ischemic brain damage in rats during early and late phases of ischemic preconditioning.
Regulation & availability
Why researchers look at it
Animal studies showed a 27% increase in nerve fiber growth and 40% faster nerve signal transmission after injury, with gene expression changes across 110 known genes — with separate chromatin experiments conducted in cultured lymphocytes. Research is mainly preclinical and includes Italian–Russian collaboration; clinical benefits remain unconfirmed, but the proposed epigenetic mechanism is distinct from any existing neuroprotective approach.
- Estimated cost
- $30-80/mo oral capsules
- FDA status
- Cortagen is not FDA-approved for any indication. No publicly disclosed Cortagen IND was identified; public databases cannot establish whether an IND is on file. Cortagen is absent from the reviewed FDA 503A and 503B nomination categories, and no routine bulk-compounding basis was verified. Absence of a Cortagen-specific enforcement action does not establish lawful human therapeutic marketing.
- WADA status
- Cortagen is not named. S0 prohibits at all times pharmacological substances not covered by later sections of the List that lack current approval by any governmental health authority for human therapeutic use. S2 is not a blanket peptide prohibition.
- Prescribability
- No — not FDA-approved Not approved for human clinical use by any major regulatory authority.
- Availability
- In Russia, Cortexin (the parent polypeptide from which Cortagen was derived) is an approved pharmaceutical, but the isolated synthetic tetrapeptide Cortagen itself is not a registered drug in any major regulatory jurisdiction.
International status
EU
Not approved
US
Not approved
Russia
Used clinically (Khavinson bioregulator protocol)
Worldwide
Limited to Russian clinical use
Regulatory timeline(9)
- 1990sVladimir Khavinson develops Cortexin (bovine brain cortex polypeptide extract) at the Saint Petersburg Institute of Bioregulation and Gerontology
- 1990sCortagen tetrapeptide (Ala-Glu-Asp-Pro) synthesized using amino acid analysis of Cortexin.
- 2000First published preclinical study — sciatic nerve regeneration in rats (Turchaninova et al., PMID: 11276314)
- 2004Gene expression microarray study published demonstrating broad transcriptional effects in mouse heart (Anisimov et al., PMID: 15159690)
- 2011Study on Cortagen in chronic brain ischemia published (Zarubina & Shabanov, PMID: 21476278)
- 2015Epigenetic regulation of aged heterochromatin study published (Khavinson & Linkova, DOI: 10.1007/s10989-014-9443-7)
- 2016Neuroprotective effects during ischemic preconditioning study published (Zarubina & Shabanov, PMID: 26902350)
- 2020No regulatory approval sought or obtained in any Western jurisdiction.
- 2026Not FDA-approved. No publicly disclosed active IND identified; confidential filing status is unknown. Cortexin (parent compound) remains an approved pharmaceutical in Russia.
Sources & FAQs
Research sources(7)
- Turchaninova et al. 2000 — Sciatic nerve regeneration study
- Anisimov et al. 2004 — Gene expression microarray study
- Zarubina & Shabanov 2011 — Chronic brain ischemia study
- Lezhava et al. 2015 — Epigenetic heterochromatin regulation
- Zarubina & Shabanov 2016 — Ischemic preconditioning neuroprotection
- Cortagen Wikipedia entry
- Vladimir Khavinson — developer of Cortagen
Frequently asked questions(4)
What is the difference between Cortagen and Cortexin?
Cortexin is a complex polypeptide mixture extracted from bovine brain cortex, approved as a pharmaceutical in Russia. Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide designed using amino acid analysis of Cortexin; the cited work does not establish it as Cortexin's primary active component. Cortagen is a single defined-sequence peptide, while Cortexin contains many peptide fractions.
Is there human clinical trial data for Cortagen?
No randomized controlled human clinical trials have been published for Cortagen. Evidence is limited to animal studies and observational reports from Russian clinical practice. The human data that does exist describes therapeutic effects on peripheral nerve recovery but lacks the rigor of placebo-controlled trials.
How is Cortagen typically administered in research?
In published animal studies, Cortagen was administered via intramuscular injection. Some sources mention intranasal and oral capsule formulations.
Is Cortagen the same as other brain peptides like Semax or Selank?
No. Cortagen is a bioregulatory peptide that works at the epigenetic level to modulate gene expression. Semax and Selank are synthetic analogs of natural neuropeptides (ACTH and tuftsin, respectively) that work primarily through neurotransmitter modulation. They have different mechanisms, sequences, and evidence bases.